
HealthEquity Cash Flow 2026-2011 | HQY
Brief overview of HealthEquity's cash movements
This overview follows the five latest available annual observations in the 2022–2026 interval.
Cash from operations increased +224.2%, from $141 million to $457.1 million. CAGR of about 34.2% indicates strong momentum.
Core operations generated cash in every available annual observation. Stability was high.
The cash conversion ratio reached 4.48x. Cash generation matched or exceeded accounting profit.
Operating cash margin decreased to 34.8% from 65.2% initially. The quality of receipts deteriorated.
Overall picture
HealthEquity's cash generation remains workable and supports the business, though some uses of cash limit flexibility.
Annual Cash Flow HealthEquity
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
457 M | 340 M | 243 M | 151 M | 141 M | 182 M | 105 M | 113 M | 81.7 M | 45.6 M | 26.5 M | 15 M | 18 M | 11.8 M | - | - |
Depreciation & Amortization |
155 M | 162 M | 153 M | 161 M | 137 M | 116 M | 55.4 M | 18.2 M | 16 M | 13.2 M | 8.6 M | 5.89 M | 4.27 M | 3.36 M | - | - |
Accounts Payables |
12.2 M | 14.4 M | 12 M | 13.9 M | 27.5 M | 1.61 M | 3.98 M | 3.52 M | 2.42 M | 3.22 M | 2.43 M | 1.3 M | - | - | - | - |
Accounts Receivables |
124 M | 118 M | 105 M | 96.8 M | 87.4 M | 72.8 M | 70.9 M | 25.7 M | 21.6 M | 17 M | 14.3 M | 9.05 M | - | - | - | - |
Total Inventories |
- | - | - | - | - | - | - | - | 215 K | 592 K | 620 K | 625 K | - | - | - | - |
All numbers in USD currency
Quarterly Cash Flow HealthEquity
| 2027-Q2 | 2027-Q1 | 2026-Q4 | 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
- | 97.5 M | - | 339 M | 201 M | 64.7 M | - | - | - | 64.7 M | - | - | - | 65.4 M | - | - | - | 31.5 M | - | 95.2 M | 47.2 M | 7.08 M | - | 90.4 M | 68.2 M | 30.9 M | - | 121 M | 68.7 M | 15 M | - | 74.1 M | 56.8 M | 25.3 M | - | 80.8 M | - | 22.7 M | - | - | 39.8 M | 15.6 M | - | 31 M | 15.5 M | 2.11 M | - | 18.8 M | 7.29 M | 1.77 M | - | 10.6 M | 5.32 M | 1.46 M | - | 12.4 M | 7.12 M | - | - | - | - | - | - | - | - | - |
Depreciation & Amortization |
38 M | 38.2 M | - | 116 M | 77.2 M | 38.7 M | - | 400 K | 500 K | 38.7 M | - | 1 M | 1.3 M | 38.9 M | - | 1.8 M | 2 M | 39 M | - | 2.9 M | 3.2 M | 39.5 M | - | 98.4 M | 64.8 M | 31.8 M | - | 85.5 M | 56.1 M | 27.5 M | - | 28.8 M | 9.72 M | 4.77 M | - | 13.5 M | 800 K | 4.52 M | - | 700 K | 7.14 M | 3.48 M | - | 9.54 M | 6.12 M | 2.95 M | 1.1 M | 5.73 M | 3.66 M | 1.75 M | 728 K | 4.19 M | 2.64 M | 1.25 M | - | 3.14 M | 1.99 M | - | - | - | - | - | - | - | - | - |
Accounts Payables |
12.2 M | 14.2 M | 14.4 M | 19.5 M | 9.6 M | 13.5 M | 12 M | 19.5 M | 9.6 M | 13.5 M | 14.4 M | 10.4 M | 10.6 M | 18.2 M | 12 M | 13.4 M | 12.5 M | - | 13.9 M | 15.8 M | 15.8 M | 13.7 M | 1.61 M | 5.24 M | 4.7 M | 9.64 M | 3.98 M | 6.75 M | 11.7 M | 7.34 M | 3.52 M | 7.97 M | 2.74 M | 1.96 M | 2.42 M | 1.5 M | 1.77 M | 3.11 M | 3.22 M | 3.3 M | 1.59 M | 1.54 M | 2.43 M | 1.58 M | 1.8 M | 1.23 M | 1.3 M | 2.41 M | 1.03 M | 990 K | 2.37 M | 908 K | 463 K | - | - | - | - | - | - | - | - | - | - | - | - | - |
Accounts Receivables |
124 M | 122 M | 118 M | 111 M | 111 M | 116 M | 105 M | 111 M | 111 M | 116 M | 118 M | 107 M | 108 M | 106 M | 105 M | 96.2 M | 92.6 M | - | 96.8 M | 87.7 M | 90.4 M | 86 M | 72.8 M | 84.1 M | 74.2 M | 74.5 M | 70.9 M | 64.3 M | 70.2 M | 69.8 M | 25.7 M | 66.6 M | 27.4 M | 27 M | 21.6 M | 24.5 M | 24.9 M | 23 M | 17 M | 21.5 M | 20.9 M | 19 M | 14.3 M | 14.1 M | 16.7 M | 15.7 M | 9.05 M | 9.92 M | 10.9 M | 10.5 M | 5.7 M | 6.05 M | 6.29 M | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Inventories |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 215 K | 164 K | 163 K | 177 K | 592 K | 169 K | 339 K | 529 K | 620 K | 944 K | 699 K | 598 K | 625 K | 815 K | 590 K | 667 K | 391 K | 756 K | 369 K | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Cash Flow Statement is one of the three key financial reports of the company HealthEquity, reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.
Main Sections of the Cash Flow Statement- Operating Activities
This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash. - Investing Activities
Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign. - Financing Activities
Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.
The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.
Cash flow statements of other stocks in the Health information services sector
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
|
Teladoc Health
TDOC
|
$ 6.26 | 0.24 % | $ 1.1 B | ||
|
10x Genomics
TXG
|
$ 65.6 | 4.71 % | $ 8.18 B | ||
|
Veeva Systems
VEEV
|
$ 264.84 | 1.3 % | $ 43.3 B | ||
|
Zhongchao
ZCMD
|
$ 0.85 | 0.29 % | $ 2.91 M | ||
|
Cerner Corporation
CERN
|
- | - | $ 27.9 B | ||
|
Change Healthcare
CHNG
|
- | - | $ 9.03 B | ||
|
Covetrus
CVET
|
- | - | $ 2.94 B | ||
|
Allscripts Healthcare Solutions
MDRX
|
- | -10.39 % | $ 886 M | ||
|
NantHealth
NH
|
- | -46.64 % | $ 10.4 M | ||
|
1Life Healthcare
ONEM
|
- | - | $ 3.37 B | ||
|
R1 RCM
RCM
|
- | - | $ 3.81 B | ||
|
Tabula Rasa HealthCare
TRHC
|
- | - | $ 255 M | ||
|
Signify Health
SGFY
|
- | -0.02 % | $ 7.21 B | ||
|
American Well Corporation
AMWL
|
$ 13.34 | 2.69 % | $ 214 M | ||
|
Evolent Health
EVH
|
$ 4.22 | 1.41 % | $ 482 M | ||
|
GoodRx Holdings
GDRX
|
$ 3.52 | 1.15 % | $ 1.25 B | ||
|
Health Catalyst
HCAT
|
$ 1.7 | 0.59 % | $ 119 M | ||
|
HealthStream
HSTM
|
$ 28.72 | 1.78 % | $ 862 M | ||
|
So-Young International
SY
|
$ 2.65 | 0.18 % | $ 206 M | ||
|
iCAD
ICAD
|
- | - | $ 102 M | ||
|
Omnicell
OMCL
|
$ 33.88 | 0.32 % | $ 1.56 B | ||
|
OptimizeRx Corporation
OPRX
|
$ 7.6 | 1.74 % | $ 141 M | ||
|
Progyny
PGNY
|
$ 27.15 | 4.66 % | $ 2.31 B | ||
|
Phreesia
PHR
|
$ 10.22 | 0.76 % | $ 611 M | ||
|
NextGen Healthcare
NXGN
|
- | - | $ 1.6 B | ||
|
Accolade
ACCD
|
- | 0.29 % | $ 206 M | ||
|
Computer Programs and Systems
CPSI
|
- | 4.4 % | $ 133 M | ||
|
Akerna Corp.
KERN
|
- | - | $ 161 M | ||
|
MTBC
MTBC
|
- | -0.58 % | $ 51.7 M | ||
|
Premier
PINC
|
- | - | $ 2.33 B | ||
|
Schrödinger
SDGR
|
$ 20.03 | 0.2 % | $ 1.47 B | ||
|
Streamline Health Solutions
STRM
|
- | - | $ 21.4 M | ||
|
SCWorx Corp.
WORX
|
- | - | $ 7.71 M |